This Is MS Multiple Sclerosis Knowledge & Support Community

Thanks dignan, still one thing I am not certain I understand about this study, is that in my mind, I would expect that Ty would cause a lowering of lesions while you are on it (compared to those on placebo). If NO "bounce back" effect was noticed, then you would expect that at the end of 3 months off the therapy, you would expect the ones who never took Ty, would be worse off than those who did take it during the trial; ie they started the 3 months from a point of more lesions.

A phase II study failed to demonstrate a difference between natalizumab treatment groups and the placebo group with regard to gadolinium enhancing lesions on MRI 3 months after discontinuation of therapy.

so if by "placebo" group they mean the ones who didn't receive Ty during the study, then during the "3 months after discontinuation of therapy" the non-placebo group progressed at a faster rate (to catch up) than the placebo group? so, to me that is a "bounce-back", limited, but still.

I think they specify enhancing lesions because those are the active or new lesions, not the accumulated lesions. Just my guess though...

Good point, and now my distrust makes me wonder why they didn't mention accumulated lesions.

I assume they have some sort of evil, world-domination plot in the works.

now your talkin!